Crescendo Biologics Ltd: Crescendo Biologics Expands its Ong

Crescendo Biologics Ltd: Crescendo Biologics Expands its Ongoing Collaboration with Takeda


Crescendo Biologics Ltd: Crescendo Biologics Expands its Ongoing Collaboration with Takeda
Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announced that it has expanded its global, multi-target discovery and development collaboration with Takeda Pharmaceutical Company Limited (Takeda) after Crescendo achieved its sixth technical milestone.
Under its ongoing collaboration and license agreement, Crescendo's proprietary transgenic platform and engineering expertise is being used to build Humabody
-based therapeutics against certain targets selected by Takeda.
The collaboration expansion gives Takeda access to a range of Crescendo's half-life extension Humabodies for use with its two Humabody programmes, previously licensed in November 2018 and July 2019, and Humabody programmes Takeda licenses in the future during the term of the collaboration expansion.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Christelle Kerouedan , Melanie Toyne Sewell , Theodora Harold , Ip Group , Takeda Pharmaceutical Company Limited , Crescendo Biologics Ltd , Oncology Drug Discovery Unit , Crescendo Biologics , Sofinnova Partners , Andera Partners , Takeda Ventures , Quan Capital , கேம்பிரிட்ஜ் , கேம்பிரிட்ஜ்ஷைர் , ஒன்றுபட்டது கிஂக்டம் , மெலனி டாய்ன் தையல் , தியோடோரா ஹரோல்ட் , இப் குழு , டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை , பிறை உயிரியல் லிமிடெட் , புற்றுநோயியல் மருந்து கண்டுபிடிப்பு அலகு , பிறை உயிரியல் , டாகேடா முயற்சிகள் , குவான் மூலதனம் ,

© 2025 Vimarsana